A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4965 (2006.01) A61K 31/44 (2006.01) C07D 401/00 (2006.01) C07D 403/00 (2006.01) C07D 405/00 (2006.01) C07D 409/00 (2006.01) C07D 411/00 (2006.01) C07D 413/00 (2006.01) C07D 417/00 (2006.01) C07D 419/00 (2006.01)
Patent
CA 2555402
The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson~s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.
La présente invention concerne de nouveaux amides tels que ceux ayant la formule (I) : (I) qui sont des modulateurs de mGluR5 utiles dans le traitement ou la prévention de maladies et de conditions dans lesquelles mGluR5 est impliqué, incluant entre autres les troubles psychiatriques et de l~humeur tels que la schizophrénie, l~anxiété, la dépression, la psychose maniacodépressive et la panique, ainsi que dans le traitement de la douleur, de la maladie de Parkinson, du dysfonctionnement cognitif, de l~épilepsie, des troubles du rythme circadien et du sommeil, tels que les troubles du sommeil causé par les trois huit et les symptômes du décalage horaire, la toxicomanie, le manque, l~obésité et d~autres maladies. L~invention concerne également des compositions pharmaceutiques comprenant ces composés. Cette invention propose également un procédé de traitement de ces maladies et conditions par l'administration d'une quantité efficace de ces nouveaux amides et/ou compositions contenant ces composés.
Bonnefous Celine
Kamenecka Theodore M.
Vernier Jean-Michel
Merck & Co. Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Bipyridyl amides as modulators of metabotropic glutamate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bipyridyl amides as modulators of metabotropic glutamate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bipyridyl amides as modulators of metabotropic glutamate... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1426960